Short answer
Azenta, Inc. (AZTA) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Ginger Zhou departed as Multiomics president without reported disagreement; advisory role continues through November 2026 for $103,500.
Azenta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Ginger Zhou departed as Multiomics president without reported disagreement; advisory role continues through November 2026 for $103,500
- William Martin appointed Multiomics president, bringing prior Maravai and Danaher genomic-medicine leadership
- Martin receives $540,000 base salary and 80% fiscal 2026 target bonus opportunity
- Martin eligible for approximately $1.7 million long-term award plus approximately $500,000 performance-based equity award
- Executive severance amendments increase change-in-control protections for Lin, Starr, and Pirogova
Item 7.01 · Regulation FD Disclosure
- Multiomics segment leadership transition announced April 7, 2026
- Leadership change may affect Multiomics strategy, execution, and operating performance
- Full transition details furnished in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Azenta, Inc. 8-K filings
Get the next AZTA 8-K as it lands
Follow AZTA for push alerts, or ask the research agent what this filing means.